Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PARG | Q86W56 | 2/20 | 0.31 |
| ▸ | APP | P05067 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19485704 | 0.89 | DGAT1 (0.41) | DGAT1RAB9ABRD4MAOAMAOB | |
| SCHEMBL15733050 | 0.82 | DGAT1 (0.54) | DGAT1 | |
| SCHEMBL15745368 | 0.75 | DGAT1 (0.39) | DGAT1CASRRAB9ACYP1A2CYP2C19 | |
| SCHEMBL15732923 | 0.75 | ROCK1 (0.45) | DGAT1RAB9AMAOBNPC1ALDH1A1 | |
| SCHEMBL16167708 | 0.74 | DHODH (0.44) | RAB9ABRD4BRPF1NPC1KDM4E | |
| SCHEMBL16167710 | 0.71 | PTK2 (0.39) | CASRRAB9ACYP1A2CYP2C19NPC1 | |
| SCHEMBL16167701 | 0.69 | EGFR (0.50) | RAB9AMAOAMAOBNPC1 | |
| SCHEMBL16167711 | 0.68 | STIM1 (0.36) | DGAT1MAPT | |
| SCHEMBL17250107 | 0.67 | KCNH2 (0.37) | DGAT1CASRMAPT | |
| SCHEMBL15745367 | 0.66 | PIM1 (0.48) | DGAT1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099979-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2018-04-12 | — | — | US | disclosed |
| US-9879031-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170305928-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2017-10-26 | — | — | US | disclosed |
| US-9796729-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-9738658-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170081342-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2017-03-23 | — | — | US | disclosed |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-12 | — | — | US | disclosed |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099979-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, DLAT | DGAT1 1/4885CASR 4787/4885RAB9A 2280/4885 |
| US-20170081342-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885CASR 4582/4885RAB9A 4045/4885 |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885CASR 4582/4885RAB9A 4045/4885 |
| US-20170305928-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, DLAT | DGAT1 1/4885CASR 4706/4885RAB9A 2292/4885 |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885CASR 4582/4885RAB9A 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.